The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Mavyret (glecaprevir and pibrentasvir)

When is Mavyret contraindicated?

Mavyret is contraindicated in patients with severe hepatic impairment. Additionally, Mavyret is contraindicated for use with atazanavir and rifampin.

The following chart provides information regarding additional medications that can have potential interactions with Mavyret. This table is not all inclusive.


Drug Class Specific Drugs Within Class Contraindicated with Mavyret
Antiarrhythmics Digoxin
Anticoagulants Dabigatran
Anticonvulsants Carbamazepine
Antimycobacterials Rifampin
Ethinyl Estradiol-Containing Products Ethinyl estradiol-containg medication such as combined oral contraceptives
Herbal Supplements St. Johns’ wort (Hypericum perforatum)
HIV-Antiviral Agents Atazanavir, Darunavir, Lopinavir, Ritonavir, Efavirenz
HMG-CoA Reductase Inhibitors Atorvastatin, Lovastatin, Simvastatin, Pravastatin, Rosuvastatin, Fluvastatin, Pitavastatin
Immunosupporessants Cyclosporine

Last Updated: October 2017

"FDA approves Mavyret for Hepatitis C." U.S. Food & Drug Administration. Retrieved October 6, 2017.

"Highlights of Prescribing Information." AbbVie Inc., Retrieved October 6, 2017.

"Mavyret Product Summary." AbbVie Inc., Retrieved October 6, 2017.

"Introducing MavyRet." AbbVie Inc., Retrieved October 6, 2017.